NTLA - Intellia Therapeutics Inc Market Cap to Sales Volume

Corporate company logo of Intellia Therapeutics Inc (NTLA)

Intellia Therapeutics (NTLA) is implementing sustainable synthesis and energy conservation while awaiting CRISPR test results, with the market having already priced in its liquidity and alliances. The company's rolling P/S on the GURU.Markets portal demonstrates a revenue valuation, where the 25.80 mark reflects the latest data. However, the risk of supply chain disruptions and challenges regarding overseas patent protection create a certain vulnerability for the business.

NTLA: Intellia P/S Multiple 07/04/2022 - 11/15/2026

Analytical breakdowns for Intellia Corp (NTLA)

- share price and consensus valuation forecast:
Price Performance Chart Intellia|NTLA - Consensus Target
- market capitalization statistics:
Market Value Intellia Corp|NTLA - Enterprise Value
- book capitalization information:
Accounting Value of a Share Intellia Therapeutics|NTLA - Book Capitalization|Market-to-Book Ratio intelliatx.com|NTLA - Aggregate Company Assets
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Intellia Therapeutics|NTLA - Long-Term Debt to Capital|Short-Term Debt to Capital intelliatx.com|NTLA - Company Debts|Debts to Book Capitalization Ratio Intellia Corp|NTLA - Company Long-Term Debts|Short-Term Debt Intellia Therapeutics|Quick Ratio intelliatx.com
- earnings and valuation multiples information:
NTLA - Net Income|Future Net Profit Intellia Therapeutics|NTLA - P/E Multiple|Market Cap to Projected Earnings Intellia|NTLA - PEG Multiple|Enterprise Value to EBITDA Ratio Intellia Therapeutics|NTLA - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Intellia Therapeutics|NTLA - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months intelliatx.com|NTLA - Net earnings per share growth this year|Projected earnings per share increase next year Intellia Therapeutics
- issuer revenue and sales details:
NTLA - Company Revenue|Company Projected Revenue Intellia Therapeutics, Inc.|NTLA - P/S Multiple|Forward P/S Multiple Intellia Corp|NTLA - Sales Growth YoY (TTM)
Fundamental company analysis:Intellia Therapeutics, Inc. - NTLA
Finished products of Intellia

The business scaling dynamics of Intellia Therapeutics (NTLA) within the CRISPR therapy sector are clearly reflected through the revenue multiple. This indicator compares market capitalization to sales volume, measuring the extent to which the asset's value is inflated relative to current cash flows, which allows investors to assess the balance between the fundamental risks of clinical trials and market expectations for the future commercialization of gene medicines.

Competing companies

TEM (Tempus AI, Inc.) - Market Capitalization-to-Revenue Ratio|Qiagen Group - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio IONS|RGEN - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Avidity Biosciences RNA|CRSP: P/S Multiple|Market Cap to Revenue Ratio WGS|RARE (Ultragenyx Pharma) - P/S Multiple|P/S Multiple Beam Therapeutics Inc.|Price-to-Revenue Ratio Sarepta Therapeutics Inc (SRPT)|Twist Bioscience - Market Cap to Revenue Ratio|10x Genomics Inc - Market Cap to Revenue|Market Cap to Sales Volume STOK (Stoke Therapeutics, Inc.)|BLFS - Price-to-Revenue Ratio|Price to Sales Wave Pharma|mazetx.com (MAZE) - Price-to-Revenue Ratio|SION - Price-to-Revenue Coefficient|PRME (Prime Medicine Inc) - P/S Multiple|Taysha Gene Therapies, Inc. - Price-to-Sales Ratio|P/S Multiple QURE|MGTX: Price-to-Sales Ratio|Price-to-Revenue Ratio REGENXBIO RGNX|SLDB: Market Cap to Revenue Ratio|OCGN: Market Cap to Revenue|PACB - P/S Multiple|BNTC (Benitec Corp) - Market Cap to Revenue|Price-to-Revenue Multiple Design Corp DSGN|Price-to-Revenue Ratio Rocket Pharmaceuticals|P/S Multiple 4D Molecular Therapeutics, Inc.|Price-to-Revenue Ratio Lexeo (LXEO)|KRRO (Korro Bio Inc.) - Market Capitalization-to-Revenue Ratio|P/S Multiple EDIT (Editas Medicine, Inc.)|P/S Multiple Silence Therapeutics Corp SLN|PRQR - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Codexis Inc CDXS|SGMO: P/S Multiple|Market Cap to Revenue Ratio NAUT|Price-to-Revenue Ratio metagenomi.co|P/S Multiple Precision BioSciences Inc.|P/S Multiple GBIO|Boundless Bio, Inc. - Market Cap to Revenue Ratio|P/S Multiple XCUR (Exicure, Inc.)|Price-to-Revenue Coefficient Imunon, Inc. (IMNN)|PHIO - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio MBIO (mustangbio.com)|RNAZ: P/S Multiple|Market Cap to Revenue Ratio BNGO|APDN (Applied DNA Corp) - P/S Multiple|BLUE: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio ImmunoPrecise (IPA)|OMGA - Price to Sales|Price-to-Revenue Ratio Singular Genomics OMIC|Market Capitalization-to-Revenue Ratio RGLS|Syros Pharmaceuticals, Inc. - P/S Multiple|Price-to-Revenue Coefficient Telesis Bio Inc. TBIO|TRACON Pharmaceuticals, Inc. (TCON) - Price-to-Revenue Ratio|Unity Biotechnology, Inc - Market Capitalization-to-Revenue Ratio